Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.

Cancer letters - 28 Apr 2024

Han Bo-Yue, Chen Chao, Luo Hong, Lin Cai-Jin, Han Xiang-Chen, Nasir Javaria, Shi Jin-Xiu, Huang Wei, Shao Zhi-Ming, Ling Hong, Hu Xin

Abstract excerpt

More than half of the breast cancer initially labeled as human epidermal growth factor receptor 2 (HER2)-negative actually exhibited low HER2 levels (IHC 1+ or IHC 2+/FISH-) and were classified as HER2-low breast cancer. Previous research emphasized the significant biological heterogeneity in HER2-low breast cancer, highlighting the importance of accurately characterizing HER2-low tumors to promote the precise...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to HER2/EGFR in Cancer Research

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 38403109
DOI: 10.1016/j.canlet.2024.216763

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.PMID 38403109Read ↗

Heterogeneity of genomic profile in patients with HER2-positive breast cancer.Semantic proximity Read ↗

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.Semantic proximity Read ↗

Genomic Alterations of Tumors in HER2-Low Breast Cancers.Semantic proximity Read ↗

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.Semantic proximity Read ↗

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study.Semantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.Semantic proximity Read ↗

The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.Semantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.Semantic proximity Read ↗

Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.Semantic proximity Read ↗

Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.